Evidence map›Paper›PMID 40386041›Full record

ArticleMolecular genetics and metabolism reports2025

GM2 activator deficiency: An ultra-rare disorder with a new case and review of 22 published cases.

Merve Yoldaş Çelik, Burcu Köşeci, Ezgi Burgaç, Kanay Yararbaş

Abstract readCase Reports
In one paragraph

Article in Molecular genetics and metabolism reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Merve Yoldaş ÇelikAdana City Training and Research Hospital, Department of Pediatric Metabolism, Adana, Turkey.
Burcu KöşeciAdana City Training and Research Hospital, Department of Pediatric Metabolism, Adana, Turkey.
Ezgi BurgaçAdana City Training and Research Hospital, Department of Pediatric Metabolism, Adana, Turkey.
Kanay YararbaşDemiroglu Bilim University Faculty of Medicine, Department of Medical Genetics, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GM2 activator deficiency (AB variant of GM2 gangliosidosis) is an ultra-rare autosomal recessive lysosomal storage disorder caused by pathogenic GM2A mutations. The loss of a functional GM2 activator protein disrupts GM2 ganglioside degradation, leading to progressive neurodegeneration. Although it shares clinical features with Tay-Sachs disease, GM2 activator deficiency remains a genetically and biochemically distinct disorder, with limited genotype-phenotype correlation due to the small number of reported cases. This report presents a 33-month-old male with an infantile-onset phenotype, characterized by nystagmus, axial hypotonia, hyperacusis, and bilateral cherry-red spots. Genetic analysis identified a homozygous likely pathogenic c.262_264del (p.Lys88del) mutation, reinforcing its potential association with early disease onset. His clinical course was marked by progressive neurodegeneration, recurrent pulmonary infections, and severe feeding difficulties requiring gastrostomy placement. In addition, previously published cases were reviewed to provide insights into the phenotypic spectrum, age of onset, and key clinical characteristics of GM2 activator deficiency. Among the 22 reported cases, 77.3 % exhibited an infantile-onset phenotype, while 18.2 % and 4.5 % had juvenile and adult-onset forms, respectively. Notably, cherry-red spots and hyperacusis were present in 94.1 % and 82.4 % of infantile cases but were strikingly absent in later-onset phenotypes. This case report, supplemented by a literature review, offers a comprehensive overview of GM2 activator deficiency and underscores the importance of early molecular diagnosis in suspected cases.

Indexed as

AB variant GM2 gangliosidosisCherry-red spotsGM2AGM2 activator deficiency

Identifiers

PMID40386041
PMCPMC12083987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.